코스닥 이야기
Quickly browse recent reports in the selected category.
-
Kosdaq at 951 level; Chunbo (278280) Hits 52-Week Low... KRW 100 Billion CB Put Option Risk Drags Down Stock Despite Defense from Advanced Semiconductor Materials
Chunbo (278280) hit a 52-week low of KRW 37,250 during trading before closing at KRW 39,650 on June 10, 2026. Despite its semiconductor materials business holding up, massive CB put option risks are weighing heavily on the stock.
-
Analyzing KOSDAQ 150 PSR Valuations Amid a 'Sidecar' Rebound: Financials and Discrepancy Ratios for Fadu, Satrec Initiative, and Hyundai Movex
Amid a sharp market rebound triggered by a KOSDAQ sidecar, this analysis evaluates the PSR valuations and financial health of three key KOSDAQ 150 candidates: Fadu, Satrec Initiative, and Hyundai Movex.
-
![[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2676d12d4578.84092915.png)
[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September
HLB faces major commercialization milestones with upcoming FDA decisions: the PDUFA target date for its liver cancer therapy on July 23, 2026, and a decision on its cholangiocarcinoma treatment expected by September 27.
-
Alteogen (196170) Enters Era of Scale Milestone Revenues, First Year of Earnings Leap Proven by Royalty Inflows
Alteogen (196170) is set to enter a massive milestone inflow phase driven by its SC platform technology, with billions in cash expected from Keytruda SC sales and new licensing deals amid resolved patent risks.
-
KOSDAQ Flirts with 1,002 Level Amidst KOSPI's Rally past 8,000: Examining Bio/Healthcare ETF Inflows and Second-Half Recovery Scenarios
KOSDAQ faces decoupling at the 1,002.44 level as KOSPI rallies past 8,000. However, persistent K-bio technology exports are driving steady inflows into KOSDAQ active healthcare ETFs, pointing to a potential H2 rebound.
-
KOSDAQ Anchors at 1,002 Level; Examining Classys' (214150) 15% US Revenue Target and Global Expansion Strategy
Global medical aesthetics leader Classys (214150) is accelerating its expansion in the US, the world's largest aesthetic medical market, presenting a long-term roadmap with a 15% revenue share target for North America.